| アブストラクト | BACKGROUND: Aducanumab, a monoclonal antibody, received approval for the treatment of Alzheimer's disease in 2021. However, it remains controversial over the security of this drug. In this study, aducanumab-related adverse events (AEs) were evaluated through data mining based on the FDA Adverse Event Reporting System (FAERS) database. RESEARCH DESIGN AND METHODS: The AE reports induced by aducanumab as the primary suspected drug were extracted from the FAERS database. The clinical characteristics of aducanumab-associated reports were analyzed. The potential new AE signals of aducanumab were explored using four disproportionality analysis methods. Furthermore, the difference in aducanumab-associated AE signals was investigated concerning sex, age, weight, dose, onset time, and continent. RESULTS: In total, 328 reports and 793 AEs associated with aducanumab were identified. Six new AEs were identified. No significant sex and weight difference in aducanumab-related signals was found. Notably, nervous system disorders, especially 'amyloid related imaging abnormality-edema/effusion' and 'amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits,' were more frequently to be reported within 121-240 days, particularly in Europe. CONCLUSIONS: This study contributes real-world evidence regarding the safety of aducanumab. |
|---|
| ジャーナル名 | Expert opinion on drug safety |
|---|
| Pubmed追加日 | 2024/12/27 |
|---|
| 投稿者 | Wu, Shuangshuang; Qi, Yiming; Jiang, Cheng; Zheng, Junxian |
|---|
| 組織名 | Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang;Province, Hangzhou, Zhejiang, China.;College of Integrated Traditional Chinese and Western Medicine Clinical Medicine,;Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical;University, Hangzhou, Zhejiang, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39726994/ |
|---|
